<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 /home/lopez/grobid/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Corticosteroid use and mortality risk in patients with perforated colonic diverticular disease: a population-based cohort study</title>
			</titleStmt>
			<publicationStmt>
				<publisher>BMJ</publisher>
				<availability status="unknown"><p>Copyright BMJ</p>
				</availability>
				<date type="published" when="2017-04">2017-04</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author role="corresp">
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><forename type="middle">H A</forename><surname>Broersen</surname></persName>
							<email>l.h.a.broersen@lumc.nl</email>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Division of Endocrinology</orgName>
								<orgName type="department" key="dep2">Department of Medicine</orgName>
								<orgName type="institution">Leiden University Medical Centre</orgName>
								<address>
									<settlement>Leiden</settlement>
									<country key="NL">The Netherlands</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><surname>Horváth-Puhó</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Department of Clinical Epidemiology</orgName>
								<orgName type="institution">Aarhus University Hospital</orgName>
								<address>
									<settlement>Aarhus</settlement>
									<country key="DK">Denmark</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">M</forename><surname>Pereira</surname></persName>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Division of Endocrinology</orgName>
								<orgName type="department" key="dep2">Department of Medicine</orgName>
								<orgName type="institution">Leiden University Medical Centre</orgName>
								<address>
									<settlement>Leiden</settlement>
									<country key="NL">The Netherlands</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Erichsen</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Department of Clinical Epidemiology</orgName>
								<orgName type="institution">Aarhus University Hospital</orgName>
								<address>
									<settlement>Aarhus</settlement>
									<country key="DK">Denmark</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">O</forename><forename type="middle">M</forename><surname>Dekkers</surname></persName>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Division of Endocrinology</orgName>
								<orgName type="department" key="dep2">Department of Medicine</orgName>
								<orgName type="institution">Leiden University Medical Centre</orgName>
								<address>
									<settlement>Leiden</settlement>
									<country key="NL">The Netherlands</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><forename type="middle">T</forename><surname>Sørensen</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Department of Clinical Epidemiology</orgName>
								<orgName type="institution">Aarhus University Hospital</orgName>
								<address>
									<settlement>Aarhus</settlement>
									<country key="DK">Denmark</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Corticosteroid use and mortality risk in patients with perforated colonic diverticular disease: a population-based cohort study</title>
					</analytic>
					<monogr>
						<title level="j" type="main">BMJ Open Gastroenterology</title>
						<title level="j" type="abbrev">BMJ Open Gastroenterol</title>
						<idno type="eISSN">2054-4774</idno>
						<imprint>
							<publisher>BMJ</publisher>
							<biblScope unit="volume">4</biblScope>
							<biblScope unit="issue">1</biblScope>
							<biblScope unit="page">e000136</biblScope>
							<date type="published" when="2017-04" />
						</imprint>
					</monogr>
					<idno type="DOI">10.1136/bmjgast-2017-000136</idno>
					<idno type="PMID">28461904</idno>
					<idno type="PMCID">PMC5387955</idno>
					<ptr type="open-access" target="https://bmjopengastro.bmj.com/content/bmjgast/4/1/e000136.full.pdf" />
					<note type="submission">Received 24 January 2017 Revised 1 March 2017 Accepted 3 March 2017</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.6.2-SNAPSHOT" ident="GROBID" when="2020-08-13T21:06+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<abstract>
				<p>Background: Corticosteroids are a potential risk factor for mortality in patients with perforated diverticular disease, due to blinding of disease severity, hampered wound healing or adrenal insufficiency. We examined mortality in corticosteroid users and non-users among patients with perforated diverticular disease. Conclusions: Corticosteroid use was associated with clearly increased mortality risk after perforated diverticular disease. Thus, use of corticosteroids should be regarded as an important clinical prognostic factor for mortality in patients with this condition.</p>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><p>Methods: A cohort study based on medical databases including all patients ≥18 years in Denmark (source population 5 289 261 inhabitants) admitted to a hospital with incident perforated diverticular disease between 2005 and 2013. 7-day, 1-month, 3-month and 1-year mortality risks in corticosteroid users and non-users were calculated using the Kaplan-Meier method, and compared with Cox proportional hazard regression adjusted for age, sex and comorbidities.</p><p>Results: The study included 4640 patients with perforated diverticular disease. Of these, 3743 (80.7%) had not used corticosteroids in the year before admission and 725 (15.6%) had been exposed to systemic corticosteroid treatment. The remaining 172 patients had been exposed to either inhaled or intestinal acting corticosteroid therapy. Mortality risk in non-users was 4.4% after 7 days and 15.6% after 1 year. This risk was doubled for corticosteroid users who filled their last prescription during the 90 days before admission, with mortality risks ranging from 14.2% after 7 days to 47.6% after 1 year. 1-year mortality risk was even higher for corticosteroid users with a first filled prescription ≤90 days before admission: 52.5%.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>INTRODUCTION</head><p>In Western countries, the prevalence of colonic diverticular disease reaches 50% among persons aged 60 and older. <ref type="bibr">1 2</ref> Although most patients remain asymptomatic, the lifetime risk for developing diverticulitis is ∼10-25%, <ref type="bibr" target="#b2">3</ref> which is known to present with perforation. <ref type="bibr">4 5</ref> The incidence of perforated diverticular disease is ∼4 per 100 000 persons each year, reported in hospital records in the UK of Great Britain and Northern Ireland and the USA. <ref type="bibr" target="#b5">6</ref> Mortality after perforated diverticular disease requiring operative intervention has been reported to be as high as</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Summary box</head><p>What is already known about this subject?</p><p>▸ Perforation is a well-known complication of diverticulitis. ▸ The incidence of perforated diverticular disease is ∼4 per 100 000 persons each year. ▸ Mortality risk after perforated diverticular disease requiring operative intervention has been reported to be 12-36% in small cohort studies. ▸ Use of corticosteroids is a potential risk factor affecting mortality in patients with perforated diverticular disease.</p><p>What are the new findings?</p><p>▸ Mortality risk was twice as high for current corticosteroids users compared with non-users. ▸ This is the first large cohort study comparing mortality risks between corticosteroid users and non-users among patients with perforated diverticular disease. We found that corticosteroid use is a strong indicator for 1-year mortality, with an absolute risk of about 50%. ▸ Our study did not indicate a relation between corticosteroid dose and mortality risk.</p><p>How might it impact on clinical practice in the foreseeable future?</p><p>▸ Use of systemic corticosteroids should be regarded as an important risk marker for mortality in patients with perforated diverticular disease. Further multiangled evidence is needed to determine whether the association between corticosteroid use and mortality risk is causal.</p><p>12-36% in small cohort studies (78-121 cases). <ref type="bibr">7 8</ref> Given this high mortality risk, a better understanding of prognostic factors associated with mortality is clearly needed. Use of corticosteroids is a potential prognostic factor affecting mortality in patients with perforated diverticular disease. Corticosteroids are widely prescribed for inflammatory diseases, malignancies and after organ transplantation, in order to inhibit an inflammatory response. <ref type="bibr" target="#b8">[9]</ref><ref type="bibr" target="#b9">[10]</ref><ref type="bibr" target="#b10">[11]</ref> At the same time, corticosteroids have been associated with bowel perforation in patients with diverticular disease. Three case-control studies reported increased ORs of 1.7 to 28.3 and one cohort study reported a relative risk of 2.2. <ref type="bibr" target="#b11">[12]</ref><ref type="bibr" target="#b12">[13]</ref><ref type="bibr" target="#b13">[14]</ref><ref type="bibr" target="#b14">[15]</ref> A recent meta-analysis showed ORs for perforation of diverticular disease after use of corticosteroids of 2.17 to 31.90. <ref type="bibr" target="#b15">16</ref> There are several reasons why mortality may be increased in patients with perforated diverticular disease who use corticosteroids. Disease severity might be masked by use of corticosteroids, <ref type="bibr" target="#b16">17</ref> leading to incorrect staging of disease severity and, consequently, inadequate treatment. <ref type="bibr" target="#b5">6</ref> Corticosteroid use might hamper wound healing as well through its anti-inflammatory effects, by suppressing cellular wound responses and by inducing diabetes, and thus increasing the risk of wound infection. <ref type="bibr" target="#b17">18</ref> A systematic review also showed that corticosteroid use may increase the risk of anastomotic leakage after colorectal surgery. <ref type="bibr" target="#b18">19</ref> Use of corticosteroids is associated with an increased risk of venous thromboembolism. <ref type="bibr" target="#b19">20</ref> In perforated diverticulitis, undiagnosed and untreated adrenal insufficiency may lead to an Addisonian crisis, which increases mortality risk in affected patients. <ref type="bibr" target="#b20">21</ref> </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Study aims</head><p>The primary aim of this study was to examine absolute mortality risks and compare 7-day, 1-month, 3-month and 1-year mortality rates in patients with perforated diverticular disease who were corticosteroid users versus non-users. The secondary aim was to examine mortality rates in patients with perforated diverticular disease who used corticosteroids administered in different forms and with different cumulative doses.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>METHODS</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Source population</head><p>The source population for this study was the entire population of Denmark (5 289 261 inhabitants) between 2005 and 2013. The study period began in 2005 because a full record of medications sold at community pharmacies and hospital-based outpatient pharmacies became available starting in 2004 in the National Health Service Prescription Database. <ref type="bibr" target="#b21">22</ref> The study was based on data from the Danish National Patient Registry, which has recorded all acute care hospital discharges since 1977 and all outpatient specialist clinic and emergency room visits since 1995. <ref type="bibr" target="#b22">23</ref> Data from the Danish Civil Registration System were used to determine vital status. <ref type="bibr" target="#b23">24</ref> Study population and follow-up The study included all adult patients (≥18 years), with and without use of corticosteroids, hospitalised with incident perforated diverticular disease between 2005 and 2013. Identification of perforated and non-perforated diverticular disease was based on International Classification of Diseases (ICD) codes (see online supplementary appendix 1 for specification of the codes). The codes used for perforated diverticular disease have a positive predictive value ranging from 0.73 to 0.75. <ref type="bibr" target="#b24">25</ref> There were no restrictions in corticosteroid dose or treatment duration. Patients diagnosed during an emergency room visit were excluded because of the low predictive value of emergency room diagnoses; diagnostic accuracy improves with more extensive diagnostic procedures. <ref type="bibr" target="#b25">26</ref> The year 2005 as start of follow-up was chosen in order to provide a 1-year prediagnosis period in which exposure to corticosteroids could be assessed similarly in all patients. Patient follow-up began on the hospital admission date for perforated diverticular disease and ended on death, emigration or end of follow-up on 30 November 2013, whichever came first.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Classification of corticosteroid use and surgical procedures</head><p>Corticosteroid use was categorised as follows, based on the National Health Service Prescription Database: <ref type="bibr" target="#b21">22</ref> I. Non-users: patients not prescribed corticosteroids during the year prior to hospital admission. II. Current users: patients using corticosteroids at time of admission, that is, the last prescription for corticosteroids was filled during the 90 days before admission. The group of current users was subdivided into new users, defined as patients who filled their first prescription ≤90 days before admission, and chronic users, which included all other current users. III. Recent users: patients who used corticosteroids until shortly before admission, that is, their last corticosteroid prescription was filled between 91 and 365 days before admission.</p><p>Analyses were performed separately for patients using systemic corticosteroids regardless of use of other forms of corticosteroids, for patients using systemic corticosteroids only, for patients using inhaled corticosteroids only, and for patients using intestinal acting corticosteroids only. There was one patient using both inhaled and intestinal acting corticosteroids.</p><p>The analysis of cumulative dose was based on categorising the 1-year cumulative dose of systemic corticosteroids among current users, calculated using prednisone dose equivalents. The cumulative dose cut-offs were ≤625, &gt;625 to 2000, &gt;2000 to 3500 and &gt;3500 mg, to provide four groups of approximately equal size.</p><p>Surgical procedures related to diverticular perforation (including a 30-day period around date of admission for diverticular disease) were categorised as explorative surgery including lavage; stoma with or without resection; and resections with primary anastomosis (see online supplementary appendix 2 for surgical codes).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Statistical analysis</head><p>Descriptive contingency tables were prepared, showing demographic characteristics and medical history (age, sex, calendar year of perforated diverticular disease diagnosis, comorbidities) of corticosteroid users and non-users.</p><p>For time-to-event analyses, the Kaplan-Meier method and Cox regression were used. Absolute mortality risks in corticosteroid users and non-users were calculated using the Kaplan-Meier method. Cox proportional hazard regression was used to compare mortality rates among the predefined categories of corticosteroid users, providing HRs for 7-day, 1-month, 3-month and 1-year mortality. Stratified analyses were performed according to type of surgery within 30 days before or after diagnosis of perforated diverticular disease.</p><p>Subgroup analyses were performed to compare mortality risks among patients taking different forms of corticosteroids (inhaled only, intestinal only and systemic only) and with different 1-year cumulative doses of systemic corticosteroid use. Also, sensitivity analyses were performed after excluding patients with malignancies, patients with inflammatory bowel disease, patients with a previous code for diverticular disease and patients with rheumatic diseases including mixed connective tissue disease.</p><p>In addition to crude analyses, we performed adjusted analyses including the following potential confounders: age, sex, use of cardiovascular medications (anticoagulants, non-steroidal anti-inflammatory drugs, ACE/angiotensin 2 receptor (A2R) inhibitors, statins, β blockers, calcium channel blockers, diuretics, selective serotonin reuptake inhibitors (SSRIs) and nitrates) <ref type="bibr" target="#b15">16</ref> during the 90 days before admission, hypertension, chronic obstructive pulmonary disease (COPD; as a proxy for smoking), liver disease or chronic pancreatitis, alcoholism-related diseases other than those affecting the liver or pancreas, inflammatory bowel disease, rheumatoid arthritis, connective tissue disease, malignancies and modified Charlson Comorbidity Index score (see online supplementary appendix 1 for specification of the codes). The modified Charlson Comorbidity Index score was calculated after exclusion of COPD, liver diseases, connective tissue disease and malignancies. These characteristics and conditions are associated with corticosteroid use and constitute potential risk factors for mortality.</p><p>We used SAS V.9.2 (SAS Institute, Cary, North Carolina, USA) for our statistical analyses. Permission from the Danish Data Protection Board was granted.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>RESULTS</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Study population</head><p>A total of 4640 patients with perforated diverticular disease were included in the study. Of these, 3743 (80.7%) had not used corticosteroids in the year before hospital admission <ref type="table" target="#tab_0">(table 1)</ref>. Of the 897 patients using corticosteroids in the prior year, 725 (80.8%) were exposed to systemic corticosteroid treatment (current and recent users combined). Of systemic corticosteroid users, 88.8% used prednisone or prednisolone, 6.9% methylprednisolone, 13.4% β-methasone, 1.5% triamcinolone and 1.0% hydrocortisone. Since the number of patients using only intestinal acting corticosteroids was small (n=28), this patient group was not analysed further. Corticosteroid users were on average older than non-users and more often female than non-users (64.8% vs 54.2%). Patients using systemic corticosteroids were more often hypertensive, more often had COPD, chronic bronchitis, emphysema or asthma, and more often had malignancies, rheumatoid arthritis, connective tissue disease or inflammatory bowel disease. Almost all patients using only inhaled corticosteroids had a diagnosis of COPD, chronic bronchitis, emphysema or asthma, but were otherwise comparable to non-users. Charlson Comorbidity Index scores were higher for all groups of corticosteroid users compared with non-users.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Mortality risk in patients with perforated colonic diverticular disease</head><p>A total of 889 patients (19.2%) with perforated diverticulitis died within 1 year following their diagnosis <ref type="table" target="#tab_1">(table 2)</ref>. Mortality risk in non-users of corticosteroids was 4.4% after 7 days, 8.8% after 30 days, 11.9% after 90 days and 15.6% after 1 year. This risk was doubled for current users of corticosteroids (adjusted HRs ranging from 1.96 (30-day mortality) to 2.10 (7-day mortality)), with mortality risks reaching 14.2% after 7 days and 47.6% after 1 year (figure 1). Mortality risk was even higher for new corticosteroid users, increasing from 15.7% 7 days postdiagnosis to 52.5% after 1 year. Among chronic corticosteroid users, mortality risks also were almost doubled, with adjusted HRs of 1.89 after 7 days and 1.74 after 1 year, and absolute mortality risks reaching 13.7% after 7 days and 45.9% after 1 year.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Mortality risk according to 1-year cumulative dose</head><p>In our study population, 124 patients had a 1-year cumulative dose ≤625 mg, 144 patients had a 1-year cumulative dose &gt;625-2000 mg, 140 patients had a 1-year cumulative dose &gt;2000-3500 mg and 86 patients had a 1-year cumulative dose &gt;3500 mg (table 3). A higher 1-year cumulative dose was not clearly associated with higher mortality risk in patients with perforated diverticular disease.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Abdominal surgical procedures</head><p>In total, 2497 (53.8%) of 4640 patients had a diverticulitis-related surgical procedure (table 1). The percentage of patients with surgery within 30 days before or after incident perforated diverticular disease was higher among systemic corticosteroid users (62.9%) compared with users of inhalation corticosteroids only (56.6%) and non-users (52.1%). Patients using systemic corticosteroids had a surgical procedure resulting in a stoma (33.8%) more often than patients not using corticosteroids (22.6%).</p><p>Within categories of surgery (explorative surgery including lavage, stoma, resection with primary anastomosis), mortality risk was increased when comparing current users to non-users. After explorative surgery, mortality risk after 1 year was 14.8% for non-users and 43.5% for current users (adjusted HR 1.12 (95% CI 0.69 to 1.83)). For patients who received a stoma, mortality risk after 1 year was 26.5% for non-users and 48.8% for current users (adjusted HR 1.37 (95% CI 1.03 to 1.82)). After a resection with primary anastomosis, mortality risk after 1 year was 15.2% for non-users and 54.1% for current users (adjusted HR 2.88 (95% CI 1.57 to 5.28)).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Subgroup and sensitivity analyses</head><p>The mortality risk among patients currently using systemic corticosteroids only (13.9% after 7 days and 48.0% after 1 year) was comparable to that among patients using systemic corticosteroids regardless of other corticosteroid use (figure 2). Compared with non-users, patients who currently used only inhaled corticosteroids also had an increased mortality risk (6.2% after 7 days and 22.3% after 1 year), with an adjusted HR ranging from 1.44 to 1.85 <ref type="table" target="#tab_3">(table 4)</ref>.</p><p>When we excluded patients with malignancies, inflammatory bowel disease, a previous code for diverticular disease, or rheumatic diseases including mixed connective tissue disease, the results of the analysis of current users of systemic corticosteroids regardless of use of other corticosteroids did not materially change for mortality risk after 7, 30, 90 days or 1 year.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>DISCUSSION</head><p>We examined mortality risks between corticosteroid users and non-users among patients with perforated diverticular disease. One-year mortality risk for current users of corticosteroids was 47.6%, double that of non-users after adjustment for confounders. One-year mortality risk was even higher for new corticosteroid users: 52.5%. Thus, corticosteroid use was clearly associated with an increased mortality risk for patients with perforated diverticular disease, continuing until at least 1 year after diagnosis, regardless of corticosteroid dose. This is the first large cohort study comparing mortality risks between corticosteroid users and non-users among patients with perforated diverticular disease. The advantage of the cohort approach is the ability to calculate absolute mortality risks, which can inform clinical practice. Our study showed that corticosteroid use is a strong indicator for 1-year mortality. An earlier study of patients with perforated peptic ulcer disease reported a 30-day mortality ratio of 2.1 after corticosteroid use. <ref type="bibr" target="#b26">27</ref> This is in line with the increased mortality risk (adjusted HR of 1.96 for 30-day mortality) that we found among current users of systemic corticosteroids in the present study.</p><p>The following study limitations need to be taken into account in interpreting our results. Determination of exposure was based on redeemed prescriptions, which may not always coincide completely with medication taken by patients. <ref type="bibr" target="#b27">28</ref> We also did not consider use of corticosteroids for longer than a year before hospital admission. Also, since prednisolone and prednisone were the most frequently used systemic steroids (89%), the results in first line apply to this patient category; whether our results also apply to patients using steroids with high first pass metabolism needs further study. Finally, perforated diverticular disease may be misclassified, <ref type="bibr">6 17</ref> as the sensitivity of relevant ICD codes is not 100% accurate. Since misclassification is probably more likely in corticosteroid users (due to blinding of symptoms and severity of the condition), mortality risk is potentially overestimated if less severe cases in corticosteroid users go undetected. <ref type="bibr" target="#b24">25</ref> However, in analyses stratified by type of surgery, which most likely harmonises the diagnostic category, a similar increased risk was found.</p><p>The central causal question is whether increased mortality risk in corticosteroid users is actually caused by corticosteroid use prior to diagnosis. Clinical arguments underlying the rationale for a causal association are masked disease severity, <ref type="bibr" target="#b16">17</ref> impaired wound healing and increased infection risk, <ref type="bibr" target="#b17">18</ref> increased risk of venous thromboembolism <ref type="bibr" target="#b19">20</ref> and unrecognised adrenal insufficiency. <ref type="bibr" target="#b28">29</ref> The risk was doubled for corticosteroid users in our fully adjusted statistical model, but residual confounding (no perfectly valid data on actual disease severity status) might still be an issue. For instance, high mortality among patients using corticosteroids may be explained partially by the underlying diseases for which corticosteroids were prescribed. However, our subgroup analyses showed no clear differences when high-risk subgroups were excluded. Regardless of the causal question, our study indicated that corticosteroid use was an important prognostic factor for mortality.</p><p>Two explanations are possible for the lack of an association observed between mortality risk and dose. First, the risk may be associated with corticosteroid use per se,  so that the maximum increase in risk is already reached at a low (but still supraphysiological) dose. Second, our classification did not distinguish between short-term, high-dose corticosteroid use and long-term, low-dose use, because the prescription database used does not provide certainty whether a drug is prescribed in high doses for short-term use, or in lower doses for longer duration. Although clinically short-term, high-dose corticosteroid use and long-term, low-dose corticosteroid use are very heterogeneous groups of patients, in our analysis according to dose, both translate into the same 1-year cumulative dose.</p><p>In conclusion, this study demonstrated that corticosteroid use was associated with increased mortality risk after diagnosis of perforated diverticular disease. Clinically, use of systemic corticosteroids should be regarded as an important risk marker for mortality among patients with this disease.</p><p>Contributors All authors contributed to the development of the study protocol and read and approved the final manuscript. EH-P extracted the data from the National Health Service Prescription Database and the Danish National Patient Registry, and performed the statistical analyses. LHAB first analysed the rough data from the statistical analyses and summarised their implications in this article. AMP related the implications to the endocrinology practice, whereas RE did the same for the gastroenterology practice. OMD paid attention to the epidemiological correctness of the implications that were made. HTS managed the entire research process and checked the final version of the article for completeness. Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work noncommercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http:// creativecommons.org/licenses/by-nc/4.0/ *HR adjusted for age, sex, use of cardiovascular medications, hypertension, COPD, liver disease or chronic pancreatitis, alcoholism-related diseases other than those affecting the liver or pancreas, inflammatory bowel disease, rheumatoid arthritis, connective tissue disease, malignancies and modified Charlson Comorbidity Index score. COPD, chronic obstructive pulmonary disease; PYR, person year.</p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Figure 2</head><label>2</label><figDesc>Cumulative mortality in patients with systemic use of corticosteroids only.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head></head><label></label><figDesc>Competing interests None declared.Provenance and peer review Not commissioned; externally peer reviewed.Data sharing statement No additional data are available.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table 1</head><label>1</label><figDesc>Baseline characteristics of corticosteroid users and non-users among patients with perforated diverticular disease</figDesc><table><row><cell></cell><cell></cell><cell></cell><cell cols="2">Systemic use</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell cols="2">regardless of</cell><cell cols="2">Systemic use</cell><cell cols="2">Inhaled use</cell></row><row><cell></cell><cell>Non-use</cell><cell></cell><cell cols="2">other uses</cell><cell>only</cell><cell></cell><cell>only</cell><cell></cell></row><row><cell></cell><cell>N</cell><cell>Per cent</cell><cell>N</cell><cell>Per cent</cell><cell>N</cell><cell>Per cent</cell><cell>N</cell><cell>Per cent</cell></row><row><cell>Total</cell><cell>3743</cell><cell>100.0</cell><cell>725</cell><cell>100.0</cell><cell>656</cell><cell>100.0</cell><cell>145</cell><cell>100.0</cell></row><row><cell>Current use</cell><cell>−</cell><cell>−</cell><cell>494</cell><cell>68.1</cell><cell>446</cell><cell>68.0</cell><cell>81</cell><cell>55.9</cell></row><row><cell>New use</cell><cell>−</cell><cell>−</cell><cell>121</cell><cell>16.7</cell><cell>109</cell><cell>16.6</cell><cell>7</cell><cell>4.8</cell></row><row><cell>Chronic use</cell><cell>−</cell><cell>−</cell><cell>373</cell><cell>51.4</cell><cell>337</cell><cell>51.4</cell><cell>74</cell><cell>51.1</cell></row><row><cell>Recent use</cell><cell>−</cell><cell>−</cell><cell>231</cell><cell>31.9</cell><cell>210</cell><cell>32.0</cell><cell>64</cell><cell>44.1</cell></row><row><cell>Age, years</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>18-59</cell><cell>1431</cell><cell>38.2</cell><cell>119</cell><cell>16.4</cell><cell>113</cell><cell>17.2</cell><cell>42</cell><cell>29.0</cell></row><row><cell>60-69</cell><cell>860</cell><cell>23.0</cell><cell>146</cell><cell>20.1</cell><cell>133</cell><cell>20.3</cell><cell>37</cell><cell>25.5</cell></row><row><cell>70-79</cell><cell>777</cell><cell>20.8</cell><cell>239</cell><cell>33.0</cell><cell>213</cell><cell>32.5</cell><cell>41</cell><cell>28.3</cell></row><row><cell>80+</cell><cell>675</cell><cell>18.0</cell><cell>221</cell><cell>30.5</cell><cell>197</cell><cell>30.0</cell><cell>25</cell><cell>17.2</cell></row><row><cell>Gender (male)</cell><cell>1713</cell><cell>45.8</cell><cell>256</cell><cell>35.3</cell><cell>232</cell><cell>35.4</cell><cell>56</cell><cell>38.6</cell></row><row><cell cols="3">Calendar year of perforated diverticular disease diagnosis</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>2005-2008</cell><cell>1556</cell><cell>41.6</cell><cell>328</cell><cell>45.2</cell><cell>294</cell><cell>44.8</cell><cell>60</cell><cell>41.4</cell></row><row><cell>2009-2013</cell><cell>2187</cell><cell>58.4</cell><cell>397</cell><cell>54.8</cell><cell>362</cell><cell>55.2</cell><cell>85</cell><cell>58.6</cell></row><row><cell>Comorbidities</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Diverticular disease of the colon without</cell><cell>897</cell><cell>24.0</cell><cell>173</cell><cell>23.9</cell><cell>151</cell><cell>23.0</cell><cell>36</cell><cell>24.8</cell></row><row><cell>perforation</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Hypertension</cell><cell>844</cell><cell>22.5</cell><cell>263</cell><cell>36.3</cell><cell>247</cell><cell>37.7</cell><cell>39</cell><cell>26.9</cell></row><row><cell>COPD, chronic bronchitis, emphysema</cell><cell>682</cell><cell>18.2</cell><cell>334</cell><cell>46.1</cell><cell>278</cell><cell>42.4</cell><cell>137</cell><cell>94.5</cell></row><row><cell>and asthma</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Liver disease and/or chronic pancreatitis</cell><cell>111</cell><cell>3.0</cell><cell>25</cell><cell>3.4</cell><cell>24</cell><cell>3.7</cell><cell>5</cell><cell>3.4</cell></row><row><cell>Alcoholism-related diseases other than</cell><cell>310</cell><cell>8.3</cell><cell>42</cell><cell>5.8</cell><cell>38</cell><cell>5.8</cell><cell>13</cell><cell>9.0</cell></row><row><cell>those affecting the liver or pancreas</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Cancer</cell><cell>503</cell><cell>13.4</cell><cell>201</cell><cell>27.7</cell><cell>189</cell><cell>28.8</cell><cell>19</cell><cell>13.1</cell></row><row><cell>Rheumatoid arthritis/connective tissue</cell><cell>138</cell><cell>3.7</cell><cell>200</cell><cell>27.6</cell><cell>186</cell><cell>28.4</cell><cell>4</cell><cell>2.8</cell></row><row><cell>disease</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Inflammatory bowel disease</cell><cell>71</cell><cell>1.9</cell><cell>40</cell><cell>5.5</cell><cell>32</cell><cell>4.9</cell><cell>4</cell><cell>2.8</cell></row><row><cell>Charlson Comorbidity Index score</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>0</cell><cell>2659</cell><cell>71.0</cell><cell>371</cell><cell>51.2</cell><cell>334</cell><cell>50.9</cell><cell>99</cell><cell>68.3</cell></row><row><cell>1-2</cell><cell>888</cell><cell>23.7</cell><cell>261</cell><cell>36.0</cell><cell>241</cell><cell>36.7</cell><cell>36</cell><cell>24.8</cell></row><row><cell>≥3</cell><cell>196</cell><cell>5.2</cell><cell>93</cell><cell>12.8</cell><cell>81</cell><cell>12.3</cell><cell>10</cell><cell>6.9</cell></row><row><cell>Surgery within 30 days before or after</cell><cell>1949</cell><cell>52.1</cell><cell>456</cell><cell>62.9</cell><cell>425</cell><cell>64.8</cell><cell>82</cell><cell>56.6</cell></row><row><cell>diagnosis of diverticulitis (total)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Explorative surgery including lavage</cell><cell>616</cell><cell>16.5</cell><cell>115</cell><cell>15.9</cell><cell>108</cell><cell>16.5</cell><cell>24</cell><cell>16.6</cell></row><row><cell>Stoma</cell><cell>845</cell><cell>22.6</cell><cell>245</cell><cell>33.8</cell><cell>228</cell><cell>34.8</cell><cell>38</cell><cell>26.2</cell></row><row><cell>Resection with primary anastomosis</cell><cell>488</cell><cell>13.0</cell><cell>96</cell><cell>13.2</cell><cell>89</cell><cell>13.6</cell><cell>20</cell><cell>13.8</cell></row></table><note>COPD, chronic obstructive pulmonary disease.</note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>Table 2</head><label>2</label><figDesc>Mortality among patients with systemic corticosteroid use, regardless of use of intestinal acting or inhaled corticosteroids compared with non-use</figDesc><table><row><cell></cell><cell></cell><cell>Absolute risk</cell><cell>Rate per 1000 PYRs</cell><cell>Crude HR</cell><cell>Adjusted HR*</cell></row><row><cell>Corticosteroid use</cell><cell>Period</cell><cell>(95% CI)</cell><cell>(95% CI)</cell><cell>(95% CI)</cell><cell>(95% CI)</cell></row><row><cell>Non-use</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_2"><head>Table 3</head><label>3</label><figDesc>Mortality among patients with current use of systemic corticosteroids, regardless of other corticosteroid use, according to 1-year cumulative dose compared with non-use Cumulative dose defined as the 1-year cumulative dose of systemic corticosteroids among current users, calculated as prednisone dose equivalents.†HR adjusted for age, sex, use of cardiovascular medication, hypertension, COPD, liver disease or chronic pancreatitis, alcoholism-related diseases other than those affecting the liver or pancreas, inflammatory bowel disease, rheumatoid arthritis, connective tissue disease, malignancies and modified Charlson Comorbidity Index score. COPD, chronic obstructive pulmonary disease; PYR, person year.</figDesc><table><row><cell>Cumulative dose of</cell><cell></cell><cell>Absolute risk</cell><cell>Rate per 1000 PYRs</cell><cell>Crude HR</cell><cell>Adjusted HR †</cell></row><row><cell>corticosteroids*</cell><cell>Period</cell><cell>(95% CI)</cell><cell>(95% CI)</cell><cell>(95% CI)</cell><cell>(95% CI)</cell></row><row><cell>Non-use</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row></table><note>*</note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_3"><head>Table 4</head><label>4</label><figDesc>Mortality among current corticosteroid users: subgroup and sensitivity analyses compared with non-use(11.4  to 17.6) 21.81 (16.70 to 26.92) 3.38 (2.56 to 4.47) 2.10 (1.52 to 2.90) 30 days 27.9 (24.2 to 32.1) 11.53 (9.60 to 13.(11.1 to 18.4) 21.94 (15.92 to 27.97) 4.03 (2.91 to 5.59) 2.22 (1.50 to 3.28) 30 days 26.3 (22.1 to 31.2) 10.80 (8.62 to 12.99) 4.04 (3.18 to 5.13) 2.00 (1.50 to 2.67) 90 days 32.9 (28.3 to 38.(11.4 to 17.8) 21.91 (16.63 to 27.20) 3.35 (2.52 to 4.46) 2.03 (1.46 to 2.83) 30 days 28.1 (24.2 to 32.4) 11.58 (9.59 to 13.57) 3.54 (2.89 to 4.34) 1.89 (1.49 to 2.40) 90 days 36.6 (32.4 to 41.2) 5.72 (4.86 to 6.59) 3.55 (2.97 to 4.24) 1.87 (1.52 to 2.29) 1 year 48.1 (43.6 to 52.8) 2.25 (1.95 to 2.54) 3.76 (3.21 to 4.39) 1.96 (1.64 to 2.36) Excluding patients with a previous code for diverticular disease 7 days 15.7 (12.4 to 19.7) 24.47 (18.28 to 30.66) 3.43 (2.53 to 4.65) 2.06 (1.45 to 2.93) 30 days 29.8 (25.5 to 34.6) 12.57 (10.26 to 14.88) 3.66 (2.94 to 4.56) 2.03 (1.58 to 2.63) 90 days 38.5 (33.8 to 43.6) 6.15 (5.16 to 7.15) 3.67 (3.03 to 4.45) 2.01 (1.61 to 2.51) 1 year 49.3 (44.4 to 54.5) 2.35 (2.01 to 2.68) 3.80 (3.20 to 4.51) 2.07 (1.70 to 2.53) Excluding patients with rheumatic diseases including mixed connective tissue disease 7 days 15.3 (11.8 to 19.6) 23.73 (17.22 to 30.25) 3.72 (2.71 to 5.10) 2.13 (1.51 to 3.01) 30 days 28.5 (23.9 to 33.6) 11.87 (9.48 to 14.25) 3.71 (2.95 to 4.67) 1.95 (1.52 to 2.51) 90 days 37.8 (32.9 to 43.3) 5.98 (4.93 to 7.02) 3.79 (3.10 to 4.62) 1.95 (1.57 to 2.42) 1 year 48.4 (43.1 to 54.0) 2.31 (1.95 to 2.67) 3.91 (3.28 to 4.67) 2.06 (1.70 to 2.49)</figDesc><table><row><cell></cell><cell></cell><cell>Absolute risk</cell><cell>Rate per 1000 PYRs</cell><cell>Crude HR</cell><cell>Adjusted HR*</cell></row><row><cell>Restrictions</cell><cell>Period</cell><cell>(95% CI)</cell><cell>(95% CI)</cell><cell>(95% CI)</cell><cell>(95% CI)</cell></row><row><cell>Non-use</cell><cell cols="2">7 days 4.4 (3.8 to 5.1)</cell><cell>6.46 (5.47 to 7.44)</cell><cell></cell><cell></cell></row><row><cell></cell><cell cols="2">30 days 8.8 (7.9 to 9.7)</cell><cell>3.12 (2.78 to 3.45)</cell><cell></cell><cell></cell></row><row><cell></cell><cell cols="2">90 days 11.9 (10.9 to 12.9)</cell><cell>1.46 (1.33 to 1.60)</cell><cell></cell><cell></cell></row><row><cell></cell><cell cols="2">1 year 15.6 (14.4 to 16.8)</cell><cell>0.51 (0.47 to 0.55)</cell><cell></cell><cell></cell></row><row><cell>Inhaled only</cell><cell cols="2">7 days 6.2 (2.6 to 14.2)</cell><cell>9.16 (1.13 to 17.18)</cell><cell cols="2">1.42 (0.58 to 3.45) 1.55 (0.60 to 3.97)</cell></row><row><cell></cell><cell cols="2">30 days 17.3 (10.6 to 27.4)</cell><cell>6.46 (3.08 to 9.84)</cell><cell cols="2">2.04 (1.20 to 3.49) 1.85 (1.04 to 3.27)</cell></row><row><cell></cell><cell cols="2">90 days 21.0 (13.6 to 31.6)</cell><cell>2.83 (1.48 to 4.17)</cell><cell cols="2">1.87 (1.15 to 3.04) 1.72 (1.03 to 2.89)</cell></row><row><cell></cell><cell cols="2">1 year 22.3 (14.7 to 33.0)</cell><cell>0.79 (0.43 to 1.16)</cell><cell cols="2">1.54 (0.96 to 2.46) 1.44 (0.88 to 2.37)</cell></row><row><cell>Systemic use only</cell><cell cols="5">7 days 13.9 (11.0 to 17.5) 21.30 (16.00 to 26.60) 3.30 (2.47 to 4.42) 2.02 (1.44 to 2.82)</cell></row><row><cell></cell><cell cols="3">30 days 28.0 (24.1 to 32.5) 11.53 (9.51 to 13.55)</cell><cell cols="2">3.56 (2.90 to 4.38) 1.96 (1.55 to 2.48)</cell></row><row><cell></cell><cell cols="2">90 days 36.0 (31.7 to 40.7)</cell><cell>5.60 (4.73 to 6.47)</cell><cell cols="2">3.52 (2.94 to 4.22) 1.92 (1.56 to 2.36)</cell></row><row><cell></cell><cell cols="2">1 year 48.0 (43.4 to 52.8)</cell><cell>2.23 (1.93 to 2.53)</cell><cell cols="2">3.77 (3.22 to 4.42) 2.04 (1.70 to 2.45)</cell></row><row><cell>Systemic use, regardless of other uses</cell><cell cols="3">7 days 14.2 45)</cell><cell cols="2">3.56 (2.92 to 4.35) 1.96 (1.56 to 2.47)</cell></row><row><cell></cell><cell cols="2">90 days 36.6 (32.5 to 41.0)</cell><cell>5.71 (4.87 to 6.54)</cell><cell cols="2">3.59 (3.02 to 4.27) 1.97 (1.62 to 2.41)</cell></row><row><cell></cell><cell cols="2">1 year 47.6 (43.2 to 52.1)</cell><cell>2.22 (1.93 to 2.50)</cell><cell cols="2">3.75 (3.22 to 4.38) 2.05 (1.72 to 2.45)</cell></row><row><cell>Excluding patients with malignancies</cell><cell cols="2">7 days 14.3 0)</cell><cell>5.00 (4.10 to 5.91)</cell><cell cols="2">3.87 (3.13 to 4.78) 1.93 (1.50 to 2.48)</cell></row><row><cell></cell><cell cols="2">1 year 42.3 (37.3 to 47.7)</cell><cell>1.85 (1.55 to 2.15)</cell><cell cols="2">3.93 (3.26 to 4.74) 2.03 (1.62 to 2.55)</cell></row><row><cell>Excluding patients with</cell><cell cols="2">7 days 14.3</cell><cell></cell><cell></cell><cell></cell></row><row><cell>inflammatory bowel disease</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row></table><note></note></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">Broersen LHA, Horváth-Puhó E, Pereira AM, et al. BMJ Open Gastro 2017;4:e000136. doi:10.1136/bmjgast-2017-000136</note>
		</body>
		<back>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Epidemiology of diverticular disease-systematic review of the literature</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">I</forename><surname>Tanase</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Paun</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">B</forename><surname>Stoica</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Chirurgia (Bucur)</title>
		<imprint>
			<biblScope unit="volume">110</biblScope>
			<biblScope unit="page" from="9" to="14" />
			<date type="published" when="2015" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Fourteen-Year Study of Hospital Admissions for Diverticular Disease in Ontario</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Eiran</forename><surname>Warner</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Eric</forename><forename type="middle">J</forename><surname>Crighton</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Rahim</forename><surname>Moineddin</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Muhammad</forename><surname>Mamdani</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ross</forename><surname>Upshur</surname></persName>
		</author>
		<idno type="DOI">10.1155/2007/943460</idno>
		<idno type="PMID">17299613</idno>
		<idno type="PMCID">PMC2657668</idno>
		<ptr type="open-access" target="http://downloads.hindawi.com/journals/cjgh/2007/943460.pdf" />
	</analytic>
	<monogr>
		<title level="j">Canadian Journal of Gastroenterology</title>
		<title level="j" type="abbrev">Canadian Journal of Gastroenterology</title>
		<idno type="ISSN">0835-7900</idno>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="97" to="99" />
			<date type="published" when="2007" />
			<publisher>Hindawi Limited</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Diverticular disease of the colon</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Neil</forename><surname>Stollman</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jeffrey</forename><forename type="middle">B</forename><surname>Raskin</surname></persName>
		</author>
		<idno type="DOI">10.1016/s0140-6736(04)15597-9</idno>
		<idno type="PMID">14987890</idno>
		<ptr type="open-access" target="http://europepmc.org/articles/pmc1272839?pdf=render" />
	</analytic>
	<monogr>
		<title level="j">The Lancet</title>
		<title level="j" type="abbrev">The Lancet</title>
		<idno type="ISSN">0140-6736</idno>
		<imprint>
			<biblScope unit="volume">363</biblScope>
			<biblScope unit="issue">9409</biblScope>
			<biblScope unit="page" from="631" to="639" />
			<date type="published" when="2004-02" />
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Incidence of perforated diverticulitis and risk factors for death in a UK population</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">R</forename><surname>Morris</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">I</forename><forename type="middle">M</forename><surname>Harvey</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">W</forename><forename type="middle">S L</forename><surname>Stebbings</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">R</forename><surname>Hart</surname></persName>
		</author>
		<idno type="DOI">10.1002/bjs.6226</idno>
		<idno type="PMID">18509877</idno>
		<idno type="ark">ark:/67375/WNG-MKXMFK0D-Q</idno>
		<idno type="istexId">63F47AFCA83BDACFE4A1B62C4EA2742D12CDD459</idno>
	</analytic>
	<monogr>
		<title level="j">British Journal of Surgery</title>
		<title level="j" type="abbrev">Br J Surg</title>
		<idno type="ISSN">0007-1323</idno>
		<idno type="ISSNe">1365-2168</idno>
		<imprint>
			<biblScope unit="volume">95</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="876" to="881" />
			<date type="published" when="2008" />
			<publisher>Wiley</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">How frequently do large bowel diverticula perforate? An incidence and cross-sectional study</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">R</forename><surname>Hart</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><forename type="middle">J</forename><surname>Kennedy</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">W</forename><forename type="middle">S</forename><surname>Stebbings</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">N</forename><forename type="middle">E</forename><surname>Day</surname></persName>
		</author>
		<idno type="DOI">10.1097/00042737-200012060-00016</idno>
	</analytic>
	<monogr>
		<title level="j">European Journal of Gastroenterology &amp; Hepatology</title>
		<title level="j" type="abbrev">European Journal of Gastroenterology &amp; Hepatology</title>
		<idno type="ISSN">0954-691X</idno>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="661" to="665" />
			<date type="published" when="2000-06" />
			<publisher>Ovid Technologies (Wolters Kluwer Health)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Position paper: management of perforated sigmoid diverticulitis</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Frederick</forename><forename type="middle">A</forename><surname>Moore</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Fausto</forename><surname>Catena</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ernest</forename><forename type="middle">E</forename><surname>Moore</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ari</forename><surname>Leppaniemi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Andrew</forename><forename type="middle">B</forename><surname>Peitzmann</surname></persName>
		</author>
		<idno type="DOI">10.1186/1749-7922-8-55</idno>
		<idno type="PMID">24369826</idno>
		<idno type="PMCID">PMC3877957</idno>
		<ptr type="open-access" target="https://wjes.biomedcentral.com/track/pdf/10.1186/1749-7922-8-55" />
	</analytic>
	<monogr>
		<title level="j">World Journal of Emergency Surgery</title>
		<title level="j" type="abbrev">World J Emerg Surg</title>
		<idno type="ISSN">1749-7922</idno>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page">55</biblScope>
			<date type="published" when="2013" />
			<publisher>Springer Nature</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Sigmoid diverticulitis with perforation and generalized peritonitis</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">David</forename><forename type="middle">M</forename><surname>Nagorney</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Martin</forename><forename type="middle">A</forename><surname>Adson</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">John</forename><forename type="middle">H</forename><surname>Pemberton</surname></persName>
		</author>
		<idno type="DOI">10.1007/bf02552645</idno>
		<idno type="PMID">3971809</idno>
	</analytic>
	<monogr>
		<title level="j">Diseases of the Colon &amp; Rectum</title>
		<title level="j" type="abbrev">Diseases of the Colon &amp; Rectum</title>
		<idno type="ISSN">0012-3706</idno>
		<imprint>
			<biblScope unit="volume">28</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="71" to="75" />
			<date type="published" when="1985-02" />
			<publisher>Ovid Technologies (Wolters Kluwer Health)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">A comparison of emergency resection and staged management in perforated diverticular disease</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">I</forename><forename type="middle">G</forename><surname>Finlay</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><forename type="middle">C</forename><surname>Carter</surname></persName>
		</author>
		<idno type="DOI">10.1007/bf02554278</idno>
		<idno type="PMID">3691263</idno>
	</analytic>
	<monogr>
		<title level="j">Diseases of the Colon &amp; Rectum</title>
		<title level="j" type="abbrev">Diseases of the Colon &amp; Rectum</title>
		<idno type="ISSN">0012-3706</idno>
		<imprint>
			<biblScope unit="volume">30</biblScope>
			<biblScope unit="issue">12</biblScope>
			<biblScope unit="page" from="929" to="933" />
			<date type="published" when="1987-12" />
			<publisher>Ovid Technologies (Wolters Kluwer Health)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Use of oral corticosteroids in the United Kingdom</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><forename type="middle">P</forename><surname>Van Staa</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><forename type="middle">G</forename><surname>Leufkens</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><surname>Abenhaim</surname></persName>
		</author>
		<idno type="DOI">10.1093/qjmed/93.2.105</idno>
		<idno type="PMID">10700481</idno>
		<idno type="PII">1460-2393</idno>
		<idno type="ark">ark:/67375/HXZ-6FQZNT18-W</idno>
		<idno type="istexId">6D9F53ECFA73E5B5B15B40C5F6CFD82B392A9C8F</idno>
		<ptr type="open-access" target="https://academic.oup.com/qjmed/article-pdf/93/2/105/4359100/930105.pdf" />
	</analytic>
	<monogr>
		<title level="j">QJM</title>
		<idno type="ISSNe">1460-2393</idno>
		<imprint>
			<biblScope unit="volume">93</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="105" to="111" />
			<date type="published" when="2000-02-01" />
			<publisher>Oxford University Press (OUP)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Hypothalamic-pituitary-adrenocortical suppression and recovery in renal transplant patients returning to maintenance dialysis</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">S</forename><surname>Rodger</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">J</forename><surname>Watson</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><surname>Sellars</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">QJM</title>
		<imprint>
			<biblScope unit="volume">61</biblScope>
			<biblScope unit="page" from="1039" to="1085" />
			<date type="published" when="1986" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">ADRENAL SUPPRESSION AFTER SHORT-TERM CORTICOSTEROID THERAPY</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Robertj.</forename><surname>Spiegel</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Alleni.</forename><surname>Oliff</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Joseph</forename><surname>Bruton</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Roberta.</forename><surname>Vigersky</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Candycek.</forename><surname>Echelberger</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Davidg.</forename><surname>Poplack</surname></persName>
		</author>
		<idno type="DOI">10.1016/s0140-6736(79)91077-8</idno>
		<idno type="PMID">85870</idno>
		<idno type="PII">S0140-6736(79)91077-8</idno>
		<idno type="ark">ark:/67375/6H6-P5SJHX7Z-Q</idno>
		<idno type="istexId">8F798D538ADF6327B7E9121B73010EBE817A1538</idno>
	</analytic>
	<monogr>
		<title level="j">The Lancet</title>
		<title level="j" type="abbrev">The Lancet</title>
		<idno type="ISSN">0140-6736</idno>
		<imprint>
			<biblScope unit="volume">313</biblScope>
			<biblScope unit="issue">8117</biblScope>
			<biblScope unit="page" from="630" to="633" />
			<date type="published" when="1979-03" />
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Anti-inflammatory drugs, analgesics and the risk of perforated colonic diverticular disease</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">R</forename><surname>Morris</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">I</forename><forename type="middle">M</forename><surname>Harvey</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">W</forename><forename type="middle">S L</forename><surname>Stebbings</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">T M</forename><surname>Speakman</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><forename type="middle">J</forename><surname>Kennedy</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">R</forename><surname>Hart</surname></persName>
		</author>
		<idno type="DOI">10.1002/bjs.4221</idno>
		<idno type="PMID">14515298</idno>
		<idno type="ark">ark:/67375/WNG-GFF09L25-S</idno>
		<idno type="istexId">6B1BC630970762A12929C378C8B310FED91734FA</idno>
	</analytic>
	<monogr>
		<title level="j">British Journal of Surgery</title>
		<title level="j" type="abbrev">Br J Surg</title>
		<idno type="ISSN">0007-1323</idno>
		<idno type="ISSNe">1365-2168</idno>
		<imprint>
			<biblScope unit="volume">90</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page" from="1267" to="1272" />
			<date type="published" when="2003" />
			<publisher>Wiley</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Perforated colonic diverticular disease: the importance of NSAIDs, opioids, corticosteroids, and calcium channel blockers</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Kristoffer</forename><surname>Piekarek</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Leif</forename><forename type="middle">A</forename><surname>Israelsson</surname></persName>
		</author>
		<idno type="DOI">10.1007/s00384-008-0555-4</idno>
		<idno type="PMID">18679693</idno>
		<idno type="ark">ark:/67375/VQC-T7BQKBL0-B</idno>
		<idno type="istexId">3868B82BE29D3D1E61F87FB0C36C49C31345AA38</idno>
	</analytic>
	<monogr>
		<title level="j">International Journal of Colorectal Disease</title>
		<title level="j" type="abbrev">Int J Colorectal Dis</title>
		<idno type="ISSN">0179-1958</idno>
		<idno type="ISSNe">1432-1262</idno>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="issue">12</biblScope>
			<biblScope unit="page" from="1193" to="1197" />
			<date type="published" when="2008-08-05" />
			<publisher>Springer Nature</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Concurrent drug use and the risk of perforated colonic diverticular disease: a population-based case-control study</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><forename type="middle">J</forename><surname>Humes</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><forename type="middle">M</forename><surname>Fleming</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">C</forename><surname>Spiller</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>West</surname></persName>
		</author>
		<idno type="DOI">10.1136/gut.2010.217281</idno>
		<idno type="PMID">20940283</idno>
		<idno type="ark">ark:/67375/NVC-C58G05L8-T</idno>
		<idno type="istexId">92B71A0CF32487FB34A4D46FEF6AD4B210574BAB</idno>
	</analytic>
	<monogr>
		<title level="j">Gut</title>
		<title level="j" type="abbrev">Gut</title>
		<idno type="ISSN">0017-5749</idno>
		<imprint>
			<biblScope unit="volume">60</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="219" to="224" />
			<date type="published" when="2010-10-12" />
			<publisher>BMJ</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Use of Acetaminophen and Nonsteroidal Anti-inflammatory Drugs: A Prospective Study and the Risk of Symptomatic Diverticular Disease in Men</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">W</forename><forename type="middle">H</forename><surname>Aldoori</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><forename type="middle">L</forename><surname>Giovannucci</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><forename type="middle">B</forename><surname>Rimm</surname></persName>
		</author>
		<idno type="DOI">10.1001/archfami.7.3.255</idno>
		<idno type="PMID">9596460</idno>
		<ptr type="open-access" target="http://pdfs.semanticscholar.org/2a55/4aa9cb2bf8e6187079fed4efd6c083905152.pdf" />
	</analytic>
	<monogr>
		<title level="j">Archives of Family Medicine</title>
		<idno type="ISSN">1063-3987</idno>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="255" to="260" />
			<date type="published" when="1998-06-01" />
			<publisher>CLOCKSS Archive</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Increased diverticular complications with nonsteriodal anti-inflammatory drugs and other medications: a systematic review and meta-analysis</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">L</forename><surname>Kvasnovsky</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Papagrigoriadis</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">I</forename><surname>Bjarnason</surname></persName>
		</author>
		<idno type="DOI">10.1111/codi.12516</idno>
		<idno type="PMID">24320820</idno>
		<idno type="ark">ark:/67375/WNG-6VMK1SZM-1</idno>
		<idno type="istexId">88AF39D5EDFAC0E794E68F7427A3B17F77A00DFC</idno>
	</analytic>
	<monogr>
		<title level="j">Colorectal Disease</title>
		<title level="j" type="abbrev">Colorectal Dis</title>
		<idno type="ISSN">1462-8910</idno>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="O189" to="O196" />
			<date type="published" when="2014-05-16" />
			<publisher>Wiley</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Surgical Management of Complicated Diverticulitis</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Richard</forename><forename type="middle">E</forename><surname>Symmonds</surname><genName>Jr</genName></persName>
		</author>
		<idno type="DOI">10.1016/s0749-0690(18)30953-4</idno>
		<idno type="PMID">3830380</idno>
	</analytic>
	<monogr>
		<title level="j">Clinics in Geriatric Medicine</title>
		<title level="j" type="abbrev">Clinics in Geriatric Medicine</title>
		<idno type="ISSN">0749-0690</idno>
		<imprint>
			<biblScope unit="volume">1</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="471" to="483" />
			<date type="published" when="1985-05" />
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Factors Affecting Wound Healing</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Guo</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><forename type="middle">A</forename><surname>Dipietro</surname></persName>
		</author>
		<idno type="DOI">10.1177/0022034509359125</idno>
		<idno type="PMID">20139336</idno>
		<idno type="PMCID">PMC2903966</idno>
	</analytic>
	<monogr>
		<title level="j">Journal of Dental Research</title>
		<title level="j" type="abbrev">J Dent Res</title>
		<idno type="ISSN">0022-0345</idno>
		<idno type="ISSNe">1544-0591</idno>
		<imprint>
			<biblScope unit="volume">89</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="219" to="229" />
			<date type="published" when="2010-02-05" />
			<publisher>SAGE Publications</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Treatment with corticosteroids and the risk of anastomotic leakage following lower gastrointestinal surgery: a literature survey</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><forename type="middle">F</forename><surname>Eriksen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">B</forename><surname>Lassen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">I</forename><surname>Gögenur</surname></persName>
		</author>
		<idno type="DOI">10.1111/codi.12490</idno>
		<idno type="PMID">24215329</idno>
		<idno type="ark">ark:/67375/WNG-CJDQPXJD-X</idno>
		<idno type="istexId">F3E951FC58910F39C5D8BC57AB41A8B0AC974052</idno>
	</analytic>
	<monogr>
		<title level="j">Colorectal Disease</title>
		<title level="j" type="abbrev">Colorectal Dis</title>
		<idno type="ISSN">1462-8910</idno>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="O154" to="O160" />
			<date type="published" when="2014-04-12" />
			<publisher>Wiley</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Use of Glucocorticoids and Risk of Venous Thromboembolism: A Nationwide Population-Based Case-Control Study</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">A</forename><surname>Johannesdottir</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><surname>Horvath-Puho</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">O</forename><forename type="middle">M</forename><surname>Dekkers</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.jvs.2013.09.021</idno>
		<ptr type="open-access" target="http://www.jvascsurg.org/article/S0741521413017151/pdf" />
	</analytic>
	<monogr>
		<title level="j">Journal of Vascular Surgery</title>
		<title level="j" type="abbrev">Journal of Vascular Surgery</title>
		<idno type="ISSN">0741-5214</idno>
		<imprint>
			<biblScope unit="volume">58</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page">1424</biblScope>
			<date type="published" when="2013-11" />
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Addisonian crisis and relative adrenal failure</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">W</forename><forename type="middle">W</forename><surname>De Herder</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">J</forename><surname>Van Der Lely</surname></persName>
		</author>
		<idno type="DOI">10.1023/A:1022938019091</idno>
	</analytic>
	<monogr>
		<title level="j">Rev Endocr Metab Disord</title>
		<imprint>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="page" from="143" to="150" />
			<date type="published" when="2003" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Existing data sources for clinical epidemiology: The Danish National Database of Reimbursed Prescriptions</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Sigrun</forename><forename type="middle">Alba</forename><surname>Johannesdottir</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Erzsébet</forename><surname>Horváth-Puhó</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Vera</forename><surname>Ehrenstein</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><surname>Schmidt</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Lars</forename><surname>Pedersen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Henrik</forename><surname>Sørensen</surname></persName>
		</author>
		<idno type="DOI">10.2147/clep.s37587</idno>
		<idno type="PMID">23204870</idno>
		<idno type="PMCID">PMC3508607</idno>
		<ptr type="open-access" target="https://www.dovepress.com/getfile.php?fileID=14474" />
	</analytic>
	<monogr>
		<title level="j">Clinical Epidemiology</title>
		<title level="j" type="abbrev">CLEP</title>
		<idno type="ISSNe">1179-1349</idno>
		<imprint>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="page">303</biblScope>
			<date type="published" when="2012-11" />
			<publisher>Dove Medical Press Ltd.</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">The Danish National Patient Register</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Elsebeth</forename><surname>Lynge</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jakob</forename><forename type="middle">Lynge</forename><surname>Sandegaard</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Matejka</forename><surname>Rebolj</surname></persName>
		</author>
		<idno type="DOI">10.1177/1403494811401482</idno>
		<idno type="PMID">21775347</idno>
		<ptr type="open-access" target="http://journals.sagepub.com/doi/pdf/10.1177/1403494811401482" />
	</analytic>
	<monogr>
		<title level="j">Scandinavian Journal of Public Health</title>
		<title level="j" type="abbrev">Scand J Public Health</title>
		<idno type="ISSN">1403-4948</idno>
		<idno type="ISSNe">1651-1905</idno>
		<imprint>
			<biblScope unit="volume">39</biblScope>
			<biblScope unit="issue">7_suppl</biblScope>
			<biblScope unit="page" from="30" to="33" />
			<date type="published" when="2011-07" />
			<publisher>SAGE Publications</publisher>
		</imprint>
	</monogr>
	<note>Suppl</note>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">The Danish Civil Registration System as a tool in epidemiology</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Morten</forename><surname>Schmidt</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Lars</forename><surname>Pedersen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Henrik</forename><forename type="middle">Toft</forename><surname>Sørensen</surname></persName>
		</author>
		<idno type="DOI">10.1007/s10654-014-9930-3</idno>
		<idno type="PMID">24965263</idno>
	</analytic>
	<monogr>
		<title level="j">European Journal of Epidemiology</title>
		<title level="j" type="abbrev">Eur J Epidemiol</title>
		<idno type="ISSN">0393-2990</idno>
		<idno type="ISSNe">1573-7284</idno>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="issue">8</biblScope>
			<biblScope unit="page" from="541" to="549" />
			<date type="published" when="2014-06-26" />
			<publisher>Springer Nature</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Positive predictive values of the International Classification of Disease, 10th edition diagnoses codes for diverticular disease in the Danish National Registry of Patients</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Erichsen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><surname>Strate</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><forename type="middle">T</forename><surname>Sørensen</surname></persName>
		</author>
		<idno type="DOI">10.2147/ceg.s13293</idno>
		<idno type="PMID">21694857</idno>
		<idno type="PMCID">PMC3108666</idno>
		<ptr type="open-access" target="https://www.dovepress.com/getfile.php?fileID=7832" />
	</analytic>
	<monogr>
		<title level="j">Clinical and Experimental Gastroenterology</title>
		<title level="j" type="abbrev">CEG</title>
		<idno type="ISSNe">1178-7023</idno>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="page">139</biblScope>
			<date type="published" when="2010-10" />
			<publisher>Dove Medical Press Ltd.</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">Diagnosis and disposition are changed when board-certified emergency physicians use CT for non-traumatic abdominal pain</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Aaron</forename><forename type="middle">Nathan</forename><surname>Barksdale</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jeff</forename><forename type="middle">Lee</forename><surname>Hackman</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Monica</forename><surname>Gaddis</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Matt</forename><forename type="middle">Christopher</forename><surname>Gratton</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.ajem.2015.07.082</idno>
		<idno type="PMID">26341808</idno>
	</analytic>
	<monogr>
		<title level="j">The American Journal of Emergency Medicine</title>
		<title level="j" type="abbrev">The American Journal of Emergency Medicine</title>
		<idno type="ISSN">0735-6757</idno>
		<imprint>
			<biblScope unit="volume">33</biblScope>
			<biblScope unit="issue">11</biblScope>
			<biblScope unit="page" from="1646" to="1650" />
			<date type="published" when="2015-11" />
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">Perforated peptic ulcer: use of pre-admission oral glucocorticoids and 30-day mortality</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Christensen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Riis</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Norgaard</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">W</forename><surname>Thomsen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><forename type="middle">M</forename><surname>Tonnesen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Larsson</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><forename type="middle">T</forename><surname>Sorensen</surname></persName>
		</author>
		<idno type="DOI">10.1111/j.1365-2036.2006.02722.x</idno>
		<idno type="PMID">16393279</idno>
	</analytic>
	<monogr>
		<title level="j">Alimentary Pharmacology and Therapeutics</title>
		<title level="j" type="abbrev">Aliment Pharmacol Ther</title>
		<idno type="ISSN">0269-2813</idno>
		<idno type="ISSNe">1365-2036</idno>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="45" to="52" />
			<date type="published" when="2006-01" />
			<publisher>Wiley</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">Glucocorticoids in systemic sclerosis: patients’ beliefs and treatment adherence</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Iudici</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">B</forename><surname>Russo</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Mitidieri</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><surname>Cuomo</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><surname>Valentini</surname></persName>
		</author>
		<idno type="DOI">10.3109/03009742.2014.957239</idno>
		<idno type="PMID">25444258</idno>
	</analytic>
	<monogr>
		<title level="j">Scandinavian Journal of Rheumatology</title>
		<title level="j" type="abbrev">Scandinavian Journal of Rheumatology</title>
		<idno type="ISSN">0300-9742</idno>
		<idno type="ISSNe">1502-7732</idno>
		<imprint>
			<biblScope unit="volume">44</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="229" to="237" />
			<date type="published" when="2014-12-02" />
			<publisher>Informa UK Limited</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">Adrenal Insufficiency in Corticosteroids Use: Systematic Review and Meta-Analysis</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Leonie</forename><forename type="middle">H A</forename><surname>Broersen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Alberto</forename><forename type="middle">M</forename><surname>Pereira</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jens</forename><forename type="middle">Otto L</forename><surname>Jørgensen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Olaf</forename><forename type="middle">M</forename><surname>Dekkers</surname></persName>
		</author>
		<idno type="DOI">10.1210/jc.2015-1218</idno>
		<idno type="PMID">25844620</idno>
		<ptr type="open-access" target="https://academic.oup.com/jcem/article-pdf/100/6/2171/10421509/jcem2171.pdf" />
	</analytic>
	<monogr>
		<title level="j">The Journal of Clinical Endocrinology &amp; Metabolism</title>
		<title level="j" type="abbrev">The Journal of Clinical Endocrinology &amp; Metabolism</title>
		<idno type="ISSN">0021-972X</idno>
		<idno type="ISSNe">1945-7197</idno>
		<imprint>
			<biblScope unit="volume">100</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="2171" to="2180" />
			<date type="published" when="2015-06" />
			<publisher>The Endocrine Society</publisher>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
